Multimodality Biomarkers for Noninvasive Assessment of the Fontan Patient
Primary Purpose
Single-ventricle, Myocardial Fibrosis
Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Exercise
Sponsored by
About this trial
This is an interventional treatment trial for Single-ventricle focused on measuring myocardial fibrosis, exercise training, Fontan
Eligibility Criteria
Inclusion Criteria:
- Presence of a congenital heart defect that leads to single ventricle physiology
- Previously performed TCPA surgery
- Current age 10 years to 40 years
- Informed consent
Exclusion Criteria:
- History of exercise intolerance (peak VO2<12ml/kg/min)
- Unstable arrhythmia at the time of screening
- Listed or being evaluated for heart transplantation
- Pregnancy or breast feeding
- Patient with pacemaker, AV block other than 1st degree block, sick sinus syndrome or other arrhythmia that may influence ability to perform exercise test or magnetic resonance imaging
Sites / Locations
- Children'sMCD
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Fontan Patients
Arm Description
All Fontan patients included in this study will be part of an exercise intervention 2-6 times/week for 3-6 months.
Outcomes
Primary Outcome Measures
Peak VO2
Improvement in Peak VO2 with 6 months of exercise training
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03263312
Brief Title
Multimodality Biomarkers for Noninvasive Assessment of the Fontan Patient
Official Title
Multimodality Biomarkers for Noninvasive Assessment of the Fontan Patient
Study Type
Interventional
2. Study Status
Record Verification Date
September 2021
Overall Recruitment Status
Active, not recruiting
Study Start Date
January 1, 2018 (Actual)
Primary Completion Date
June 2025 (Anticipated)
Study Completion Date
June 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Maria Bano
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a single center prospective longitudinal exercise training study and will enroll approximately 50 Fontan patients and 20 controls of a similar age, gender, BMI and physical activity level between the ages of 10-40 years.
Participants will undergo an MRI of the Fontan circulation. This will include imaging of the heart, lung and liver. This will include specific imaging for tissue characterization and assessment of myocardial fibrosis, liver fibrosis and disproportionate pulmonary blood flow. The investigators will then draw blood (approximately 10 ml) for assessment of serum biomarkers and circulating microRNAs of interest. The participants will undergo exercise testing and will then start a 3-6 month long cardiac rehabilitation program. After the 3-6 month study period the participants will return back for a follow up and repeat all the testing completed at enrollement.
Detailed Description
This is a single center prospective longitudinal study and will enroll approximately 50 Fontan patients and 20 controls of a similar age, gender, BMI and physical activity level between the ages of 10-40 years. The investigators will enroll from pediatric cardiology and heart failure clinics and inpatient care units at Children's Health Dallas, adult congenital heart disease clinics and inpatient care units at Clements University Hospital and the Clinical Heart Center. This study will evaluate the multimodality biomarkers for assessment of Fontan circulation including heart, liver and lung and change in these markers with exercise training.
Participants will receive an MRI of the Fontan circulation. This will include imaging of the heart, lung and liver. A blood draw (approximately 10 ml) for assessment of serum biomarkers and circulating microRNAs of interest will be completed. The participants will also complete exercise testing and will then start a 3-6 month long cardiac rehabilitation program. Frequent phone follow up (conducted by the research staff) and regular download of data from heart rate monitors will ensure adherence.
After the 3-6 month study period the participants will return for a follow up and repeat all testing completed at enrollment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Single-ventricle, Myocardial Fibrosis
Keywords
myocardial fibrosis, exercise training, Fontan
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Fontan Patients
Arm Type
Experimental
Arm Description
All Fontan patients included in this study will be part of an exercise intervention 2-6 times/week for 3-6 months.
Intervention Type
Behavioral
Intervention Name(s)
Exercise
Other Intervention Name(s)
Training
Intervention Description
Exercise training all patients enrolled.
Primary Outcome Measure Information:
Title
Peak VO2
Description
Improvement in Peak VO2 with 6 months of exercise training
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Presence of a congenital heart defect that leads to single ventricle physiology
Previously performed TCPA surgery
Current age 10 years to 40 years
Informed consent
Exclusion Criteria:
History of exercise intolerance (peak VO2<12ml/kg/min)
Unstable arrhythmia at the time of screening
Listed or being evaluated for heart transplantation
Pregnancy or breast feeding
Patient with pacemaker, AV block other than 1st degree block, sick sinus syndrome or other arrhythmia that may influence ability to perform exercise test or magnetic resonance imaging
Facility Information:
Facility Name
Children'sMCD
City
Irving
State/Province
Texas
ZIP/Postal Code
75063
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Multimodality Biomarkers for Noninvasive Assessment of the Fontan Patient
We'll reach out to this number within 24 hrs